Last 27 quarters of trend data · Healthcare · Ophthalmology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.33 | 4.69 | 3.93 | 4.65 | 5.77 | 5.33 | 4.18 | 6.45 | 8.04 | 6.56 | 6.30 | 11.62 | 12.37 | 72.71 | — | 33.61 | 9.41 | — | 5.81 | 161.57 | 343.36 |
| — | -12.1% | -6.0% | -27.9% | -28.2% | -18.7% | -33.6% | -44.5% | -35.0% | -91.0% | — | -65.4% | +31.4% | — | — | -79.2% | -97.3% | — | -19.6% | +2971.7% | — | |
| P/B Ratio | 8.35 | 35.08 | 7.88 | 8.64 | 10.20 | 7.56 | 5.16 | 5.90 | 9.51 | 5.32 | 4.08 | 4.66 | 3.28 | 2.55 | 3.28 | 1.94 | 1.95 | 2.25 | 1.60 | 2.33 | 2.78 |
| — | +364.2% | +52.7% | +46.3% | +7.3% | +42.2% | +26.6% | +26.6% | +189.6% | +108.7% | +24.3% | +140.5% | +68.3% | +13.1% | +104.5% | -17.0% | -29.9% | -9.3% | -51.5% | -39.2% | -46.9% | |
| P/FCF | 77.70 | — | 10.89 | — | 67.51 | 38.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.2% | 92.9% | 93.0% | 94.2% | 92.8% | 79.3% | 93.9% | 93.3% | 92.6% | 93.3% | 92.6% | 94.0% | 90.7% | 79.9% | — | 89.8% | 96.0% | — | 96.6% | 93.9% | 107.1% |
| — | +17.1% | -0.9% | +0.9% | +0.2% | -15.0% | +1.4% | -0.7% | +2.1% | +16.8% | — | +4.7% | -5.5% | — | — | -4.3% | -10.4% | — | -0.1% | -2.3% | — | |
| Operating Margin | -15.7% | -340.3% | -11.4% | -3.8% | -5.3% | -12.2% | -21.6% | -33.5% | -36.8% | -52.3% | -81.6% | -136.5% | -339.9% | -2187.9% | — | -998.1% | -150.6% | — | -34.2% | -3621.7% | -4274.6% |
| — | -2680.0% | +47.0% | +88.7% | +85.7% | +76.6% | +73.5% | +75.4% | +89.2% | +97.6% | — | +86.3% | -125.7% | — | — | +72.4% | +96.5% | — | -203.4% | -11401.2% | — | |
| Net Margin | -14.7% | -343.5% | -10.7% | -4.3% | -5.5% | -10.6% | -19.8% | -32.1% | -34.8% | -48.7% | -81.6% | -129.4% | -320.4% | -2092.4% | — | -936.8% | -136.0% | — | -37.6% | -3754.7% | -4393.8% |
| — | -3139.7% | +46.2% | +86.6% | +84.1% | +78.2% | +75.7% | +75.2% | +89.1% | +97.7% | — | +86.2% | -135.6% | — | — | +75.1% | +96.9% | — | -231.4% | -12303.8% | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -23.4% | -296.5% | -5.3% | -2.0% | -2.5% | -3.8% | -6.0% | -8.9% | -10.0% | -9.6% | -12.6% | -15.1% | -20.4% | -21.7% | -19.6% | -12.8% | -6.9% | -10.6% | -3.1% | -12.8% | -8.6% |
| — | -7766.3% | +11.5% | +77.3% | +75.3% | +60.6% | +52.3% | +41.5% | +51.0% | +55.9% | +35.5% | -18.4% | -196.8% | -104.1% | -531.6% | +0.2% | +19.9% | -25.7% | -192.4% | -317.5% | +44.5% | |
| ROA | -14.1% | -119.7% | -3.1% | -1.2% | -1.5% | -2.4% | -4.1% | -5.7% | -6.1% | -6.2% | -9.2% | -11.6% | -15.7% | -17.1% | -15.7% | -10.7% | -5.9% | -9.2% | -2.6% | -11.2% | -8.0% |
| — | -4796.5% | +23.8% | +78.7% | +75.1% | +60.7% | +55.4% | +50.8% | +60.9% | +63.7% | +41.6% | -9.0% | -168.0% | -86.1% | -493.9% | +5.0% | +27.2% | -15.4% | -183.4% | -299.8% | +7.4% | |
| ROIC | -23.4% | -346.1% | -5.3% | -1.6% | -2.1% | -3.6% | -6.1% | -8.9% | -10.9% | -13.6% | -19.6% | -49.5% | -344.0% | -73.9% | -24.8% | -13.7% | -11.6% | -69.4% | — | — | — |
| — | -9639.1% | +13.2% | +82.5% | +80.4% | +73.9% | +68.9% | +81.9% | +96.8% | +81.6% | +21.1% | -262.2% | -2864.6% | -6.5% | — | — | — | +54.2% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.85 | 0.26 | 0.25 | 0.27 | 0.25 | 0.22 | 0.21 | 0.32 | 0.30 | 0.29 | 0.11 | 0.15 | 0.14 | 0.17 | 0.15 | 0.10 | 0.10 | 0.09 | 0.14 | 0.01 |
| — | +246.1% | +17.4% | +20.3% | -15.5% | -19.2% | -23.9% | +90.6% | +110.4% | +116.0% | +68.8% | -23.8% | +46.4% | +42.2% | +86.2% | +6.3% | +823.6% | +663.5% | +719.6% | +3603.0% | +126.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.85 | 1.96 | 3.20 | 3.74 | 3.85 | 4.29 | 5.26 | 5.57 | 4.42 | 5.42 | 7.03 | 8.01 | 6.93 | 11.15 | 12.43 | 15.74 | 14.61 | 16.40 | 21.36 | 14.18 | 15.33 |
| — | -54.2% | -39.2% | -32.8% | -12.9% | -20.9% | -25.2% | -30.5% | -36.2% | -51.4% | -43.4% | -49.1% | -52.5% | -32.0% | -41.8% | +11.0% | -4.7% | -9.1% | +11.2% | -25.1% | -51.6% | |
| Quick Ratio | 3.82 | 1.94 | 3.17 | 3.71 | 3.82 | 4.25 | 5.21 | 5.54 | 4.39 | 5.38 | 6.99 | 7.92 | 6.85 | 11.15 | 12.43 | 15.74 | 14.61 | 16.40 | 21.36 | 14.18 | 15.33 |
| — | -54.4% | -39.1% | -33.0% | -13.0% | -20.9% | -25.4% | -30.0% | -35.9% | -51.8% | -43.8% | -49.7% | -53.1% | -32.0% | -41.8% | +11.0% | -4.7% | -9.1% | +11.2% | -25.1% | -51.6% | |
| Interest Coverage | -6.20 | -302.75 | -6.34 | -3.38 | -1.85 | -5.95 | -8.64 | -11.04 | -9.57 | -9.06 | -14.78 | -35.35 | -41.37 | -44.67 | -37.56 | -33.28 | -18.65 | -34.64 | -9.56 | -63.04 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TARS stock.
Tarsus Pharmaceuticals, Inc.'s current P/E is -4.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Tarsus Pharmaceuticals, Inc.'s current operating margin is -15.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Tarsus Pharmaceuticals, Inc.'s business trajectory between earnings reports.